

INSMED INC  
Form 8-K  
May 03, 2007

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

---

**FORM 8-K**

---

**CURRENT REPORT PURSUANT**  
**TO SECTION 13 OR 15(D) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): May 3, 2007**

---

**INSMED INCORPORATED**

**(Exact Name of Registrant as Specified in Its Charter)**

---

**Virginia**

**(State or Other Jurisdiction of Incorporation)**

**0-30739**  
**(Commission File Number)**

**54-1972729**  
**(IRS Employer**

**Identification No.)**

**8720 Stony Point Parkway, Suite 200, Richmond, Virginia**  
**(Address of Principal Executive Offices)**

**23235**  
**(Zip Code)**

**(804) 565-3000**

**(Registrant's Telephone Number, Including Area Code)**

## Edgar Filing: INSMED INC - Form 8-K

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**INFORMATION TO BE INCLUDED IN THE REPORT**

**Section 8 Other Events**

**Item 8.01. Other Events.**

On May 3, 2007 Insmmed Incorporated published a press release announcing positive results from a Phase II investigator-sponsored study of the company's drug, IPLEX, in patients with myotonic muscular dystrophy (DM1). A copy of the press release is attached hereto as Exhibit 99.1.

The information contained herein, including the Exhibit attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release issued by Insmmed Incorporated on May 3, 2007

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 3, 2007

**Insmmed Incorporated**

By: /s/ Kevin P. Tully  
Name: Kevin P. Tully C.G.A.,  
Title: Executive Vice President & Chief Financial Officer

- 3 -

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release issued by Insmmed Incorporated on May 3, 2007

- 4 -